{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T09:07:01Z","timestamp":1772356021945,"version":"3.50.1"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Pyruvate kinase (PK) deficiency is a rare enzyme-linked glycolytic defect resulting in mild-to-severe chronic persistent erythrocyte hemolysis. The disease is an autosomal recessive trait caused by mutations in the PK liver and red blood cell gene characterized by insufficient erythrocyte PK activity. PK deficiency is most diagnosed in persons of northern European descent and managed with packed red blood cell transfusions, chelation, and splenectomy with cholecystectomy. Mitapivat is the first approved therapy indicated for hemolytic anemia in adults with PK deficiency with the potential for delaying splenectomy in mild\u2013moderate disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Mechanism of Action, Pharmacodynamics, and Pharmacokinetics:<\/jats:title>\n            <jats:p>Mitapivat is a PK activator that acts by allosterically binding to the PK tetramer and increases PK activity. The red blood cell form of PK is mutated in PK deficiency, which leads to reduced adenosine triphosphate, shortened red blood cell lifespan, and chronic hemolysis. The half-life of elimination is 3\u20135 hours, with 73% bioavailability, 98% plasma protein binding, and a median duration of response of 7 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical Trials:<\/jats:title>\n            <jats:p>Mitapivat has been investigated through various clinical trials for different therapeutic indications. Pivotal trials that serve the primary focus throughout this article are ACTIVATE, ACTIVATE-T, and RISE. ACTIVATE is a phase 3, randomized, double-blind, placebo-controlled study that evaluated the efficacy and safety of mitapivat in adult patients who were not receiving regular blood transfusions. Contrarily, ACTIVATE-T explored the safety and efficacy of mitapivat in adults with PK deficiency who received regular blood transfusions. Both trials demonstrated favorable use of mitapivat in PK deficiency. Focusing on another indication, the ongoing RISE trial investigates the optimal dosage of mitapivat in sickle cell disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Therapeutic Advance:<\/jats:title>\n            <jats:p>Mitapivat is an appropriate treatment for adults with PK deficiency requiring transfusions and may be considered for patients with symptomatic anemia who do not require transfusions and\/or PK deficiency with compensated hemolysis without overt anemia.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mjt.0000000000001663","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T21:18:12Z","timestamp":1694812692000},"page":"e433-e438","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Mitapivat: A Quinolone Sulfonamide to Manage Hemolytic Anemia in Adults With Pyruvate Kinase Deficiency"],"prefix":"10.1097","volume":"30","author":[{"given":"Josef","family":"Wills","sequence":"first","affiliation":[{"name":"Global Scientific Communications Rare Blood Disorders, Sanofi, Cambridge, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Horenstein","sequence":"additional","affiliation":[{"name":"Gastroenterology, Dupilumab, Sanofi, Cambridge, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Kim","sequence":"additional","affiliation":[{"name":"Global Scientific Communications Rare Blood Disorders, Sanofi, Cambridge, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew A.","family":"Silva","sequence":"additional","affiliation":[{"name":"Massachusetts College of Pharmacy and Health Sciences, School of Pharmacy, Worcester, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4406-9304","authenticated-orcid":false,"given":"Lorena","family":"Dima","sequence":"additional","affiliation":[{"name":"Transilvania University, Faculty of Medicine, Department of Fundamental Disciplines and Clinical Prevention, Brasov, Romania."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,9]]},"reference":[{"key":"R3-20250616","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.3324\/haematol.2019.241141","article-title":"Molecular heterogeneity of pyruvate kinase deficiency","volume":"105","author":"Bianchi","year":"2020","journal-title":"Haematologica"},{"key":"R8-20250616","article-title":"Inc. Agios announces FDA approval of PYRUKYND\u00ae (mitapivat) as first disease-modifying therapy for hemolytic anemia in adults with pyruvate kinase deficiency","journal-title":"GlobeNewswire News Room"},{"key":"R10-20250616","doi-asserted-by":"crossref","first-page":"204062072110660","DOI":"10.1177\/20406207211066070","article-title":"Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias","volume":"12","author":"Al-Samkari","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"R11-20250616","doi-asserted-by":"crossref","first-page":"e144206","DOI":"10.1172\/JCI144206","article-title":"The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a \u03b2-thalassemia mouse model","volume":"131","author":"Matte","year":"2021","journal-title":"J Clin Invest"},{"key":"R12-20250616","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1182\/blood.2019000945","article-title":"Management of pyruvate kinase deficiency in children and adults","volume":"136","author":"Grace","year":"2020","journal-title":"Blood"},{"key":"R13-20250616","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.molmed.2023.02.005","article-title":"Updates and advances in pyruvate kinase deficiency","volume":"29","author":"Luke","year":"2023","journal-title":"Trends Mol Med"},{"key":"R14-20250616","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2147\/JBM.S353907","article-title":"Pyruvate kinase deficiency: Current Challenges and future prospects","volume":"13","author":"Fattizzo","year":"2022","journal-title":"J Blood Med"},{"key":"R15-20250616","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1182\/blood-2016-11-753525","article-title":"AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency","volume":"130","author":"Kung","year":"2017","journal-title":"Blood"},{"key":"R16-20250616","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3324\/haematol.2019.238865","article-title":"AG-348 (mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes","volume":"106","author":"Rab","year":"2020","journal-title":"Haematologica"},{"key":"R17-20250616","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/cpdd.604","article-title":"Phase 1 single- and multiple-ascending-dose randomized studies of the safety, pharmacokinetics, and pharmacodynamics of AG-348, a first-in-class allosteric activator of pyruvate kinase R, in healthy volunteers","volume":"8","author":"Yang","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"key":"R18-20250616","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1056\/NEJMoa1902678","article-title":"Safety and efficacy of mitapivat in pyruvate kinase deficiency","volume":"381","author":"Grace","year":"2019","journal-title":"N Engl J Med"},{"key":"R22-20250616","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(22)00214-9","article-title":"Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (activate-T): a multicentre, open-label, single-arm, phase 3 trial","volume":"9","author":"Glenth\u00f8j","year":"2022","journal-title":"Lancet Haematol"},{"key":"R23-20250616","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1182\/blood-2021-145398","article-title":"Mitapivat (AG-348) demonstrates safety, tolerability, and improvements in anemia, hemolysis, oxygen affinity, and hemoglobin S polymerization kinetics in adults with sickle cell disease: a phase 1 dose escalation study","volume":"138","author":"Xu","year":"2021","journal-title":"Blood"},{"key":"R24-20250616","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1182\/blood-2021-147317","article-title":"P1565: mitapivat improves ineffective erythropoiesis and reduces iron overload in patients with pyruvate kinase deficiency","volume":"138","author":"van Beers","year":"2021","journal-title":"Blood"},{"key":"R25-20250616","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa2116634","article-title":"Mitapivat versus placebo for pyruvate kinase deficiency","volume":"386","author":"Al-Samkari","year":"2022","journal-title":"N Engl J Med"},{"key":"R26-20250616","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.1182\/blood-2022-169125","article-title":"Long-term hemoglobin response and reduction in transfusion burden are Maintained in patients with pyruvate kinase deficiency treated with mitapivat","volume":"140","author":"Grace","year":"2022","journal-title":"Blood"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MJT.0000000000001663","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T22:05:12Z","timestamp":1750111512000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MJT.0000000000001663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":16,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0000000000001663","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}